Literature DB >> 20190794

Hormonal therapies: ADT for prostate cancer: true love or heartbreak?

Jason A Efstathiou, William U Shipley, Anthony L Zietman, Matthew R Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20190794      PMCID： PMC2900769          DOI： 10.1038/nrclinonc.2010.12

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy.

Authors:  David C Beyer; Timothy McKeough; Theresa Thomas
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-04-01       Impact factor: 7.038

2.  The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study.

Authors:  Michael J Barry; Michael A Delorenzo; Elizabeth S Walker-Corkery; F Lee Lucas; David C Wennberg
Journal:  BJU Int       Date:  2006-07-28       Impact factor: 5.588

3.  Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.

Authors:  Nancy L Keating; A James O'Malley; Matthew R Smith
Journal:  J Clin Oncol       Date:  2006-09-20       Impact factor: 44.544

Review 4.  Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugs.

Authors:  June M McKoy; E Allison Lyons; Eniola Obadina; Kenneth Carson; A Simon Pickard; Paul Schellhammer; David McLeod; Cynthia E Boyd; Norene McWilliams; Oliver Sartor; Glen T Schumock; Kathryn McCaffery; Charles L Bennett
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

5.  Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.

Authors:  Jason A Efstathiou; Kyounghwa Bae; William U Shipley; Gerald E Hanks; Miljenko V Pilepich; Howard M Sandler; Matthew R Smith
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

6.  Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction.

Authors:  Akash Nanda; Ming-Hui Chen; Michelle H Braccioforte; Brian J Moran; Anthony V D'Amico
Journal:  JAMA       Date:  2009-08-26       Impact factor: 56.272

7.  Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

Authors:  Mack Roach; Kyounghwa Bae; Joycelyn Speight; Harvey B Wolkov; Phillip Rubin; R Jeffrey Lee; Colleen Lawton; Richard Valicenti; David Grignon; Miljenko V Pilepich
Journal:  J Clin Oncol       Date:  2008-01-02       Impact factor: 44.544

8.  Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions.

Authors:  Anthony V D'Amico; James W Denham; Juanita Crook; Ming-Hui Chen; Samuel Z Goldhaber; David S Lamb; David Joseph; Keen-Hun Tai; Shawn Malone; Charles Ludgate; Allison Steigler; Philip W Kantoff
Journal:  J Clin Oncol       Date:  2007-06-10       Impact factor: 44.544

9.  Impact of androgen deprivation therapy on cardiovascular disease and diabetes.

Authors:  Shabbir M H Alibhai; Minh Duong-Hua; Rinku Sutradhar; Neil E Fleshner; Padraig Warde; Angela M Cheung; Lawrence F Paszat
Journal:  J Clin Oncol       Date:  2009-06-08       Impact factor: 44.544

10.  Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.

Authors:  Jason A Efstathiou; Kyounghwa Bae; William U Shipley; Gerald E Hanks; Miljenko V Pilepich; Howard M Sandler; Matthew R Smith
Journal:  Eur Urol       Date:  2008-01-15       Impact factor: 20.096
  10 in total
  1 in total

1.  Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.

Authors:  Justin C Voog; Rebecca Paulus; William U Shipley; Matthew R Smith; David G McGowan; Christopher U Jones; Jean-Paul Bahary; Kenneth L Zeitzer; Luis Souhami; Mark H Leibenhaut; Marvin Rotman; Siraj M Husain; Elizabeth Gore; Adam Raben; Susan Chafe; Howard M Sandler; Jason A Efstathiou
Journal:  Eur Urol       Date:  2015-09-09       Impact factor: 20.096
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.